Loading...
•
Dec 31, 2023
Oncology Institute Q4 2023 Earnings Report
The Oncology Institute's Q4 2023 financial performance was presented.
Key Takeaways
The Oncology Institute is positioned for substantial growth, focusing on its value-based care model within the expanding oncology market. The company's model aims to improve care quality and reduce costs. TOI's revenue growth is demonstrated by its increase in value-based members and expansion into new markets.
TOI is an early market leader in the oncology market.
The company operates with a proven and scalable model.
TOI is well-capitalized, employing a disciplined deployment strategy.
The company aims to provide high-quality, affordable care to more patients through platform growth.
Revenue by Segment
Forward Guidance
The Oncology Institute projects revenue between $400 million and $415 million, gross profit between $68 million and $79 million, and adjusted EBITDA between $(8) million and $(18) million for the year 2024.
Positive Outlook
- New contracts
- Expand covered lives
- New clinics & providers
- Improve unit economics
- Medicare direct contracting
Challenges Ahead
- Achievement of the anticipated results is subject to risks and uncertainties, including those disclosed in its filings with the U.S. Securities and Exchange Commission.
- The outlook does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account the impact of TOI's acquisitions, dispositions or financings.
- TOI's outlook assumes a largely reopened global market, which would be negatively impacted if closures or other restrictive measures are reimplemented.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...